The research collaboration will start with the examination of the seven transporters cited by the International Transporter Consortium and the FDA as the most clinically relevant to transporter-related
Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. Sanofi-aventis claims that GetGoal-X is the first head-to-head study
Camposomes are phospholipid nanoencapsulated camptothecins used to treat pancreatic and other cancers. The subcontract is in support of the National Cancer Institute (NCI) Alliance for Nanotechnology, and the
Paladin’s product line includes both over-the-counter (OTC) and prescription drugs such as Zincofax for diaper rash, Anbesol for teething, Cerumol for ear wax removal, Twinject for anaphylaxis, and
For the fourth quarter of 2010, the net income attributable to Pfizer was $2.89bn, compared to $767m for the same period in 2009. For the full year ended
For the fourth quarter of 2010, the company has generated net income of $271.75m, compared to $306m for the same period in 2009. However, the income from operations
This has led the net income rise to 67.4bn yen ($823m) in the period ended 31 December 2010 from 53.9bn yen a year earlier. This has also translated
The Versus EVM provides users access to patient, staff and equipment locations on mobile devices as it is synced to the Versus Advantages Real-time Locating System (RTLS). This
iPierian has assigned the iPSC patent estate it previously acquired from Bayer Schering Pharma in 2008 to Kyoto University. In turn, Kyoto University and iPS Academia Japan have
The randomized, double-blind, placebo-controlled Phase III trial will evaluate the safety and efficacy of GALNS in patients with MPS IVA. In the study, patients will receive doses of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.